Ketamine to Prevent PPD After Cesarean

• Status: Completed
• Trial end date: 2021-08-09
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators plan to randomise participants to receive ketamine or placebo control subcutaneously or by 40-minute intravenous infusions and will follow them up for 42 days to assess the incidence of postpartum depression. This feasibility pilot study is designed to explore the adequacy of the study procedures and tolerability of the interventions.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Ketamine

Criteria

Inclusion criteria:

• Term pregnancy

• Age 18-45 years of age

• Scheduled cesarean delivery under neuraxial anesthesia

Exclusion criteria:

• ASA classification IV or V

• History of psychotic episodes

• History of allergy to ketamine

• Inability to communicate in English or any other barrier to providing informed consent